Extension of Confidentiality for R&D Fee from Vanda Pharmaceuticals
Received R&D fee from Vanda Pharmaceuticals for joint new drug development (amount undisclosed)
Amount exceeds 10% of 2022 revenue (approx. KRW 2.3B), subject to mandatory disclosure
Confidentiality extended from 2026-04-30 to 2026-05-31 at Vanda's request (correction filing)
Revenue recognized as R&D income
KOSDAQ Filing Information
Filing: [Correction of Description] Major Management Matters Related to Investment Decision (Receipt of Research and Development Costs for Joint New Drug R&D)